Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, and Immunotherapy and Immune Responses.
Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Combining Targeted Therapy With Immunotherapy in <i>BRAF</i>-Mutant Melanoma: Promise and Challenges
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors